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Abstract. The airways are verified as a relevant route to improve antibody therapeutic
index with superior lung concentration but limited passage into systemic blood stream. The
current research aimed to process spray-dried (SD) powder of Infliximab to assess the
feasibility of respiratory delivery of antibody for local suppression of lung-secreted tumor
necrosis factor α (TNFα). Molecular and structural stability of powders were determined
through size exclusion chromatography (SEC-HPLC) and Fourier transform infrared (FTIR)
spectroscopy. Particle properties were characterized by laser light scattering, twin stage
impinger (TSI), and scanning electron microscopy (SEM). In vitro biological activity was
quantified applying L-929 cell line. Ovalbumin (OVA)-challenged balb/c mice were employed
to evaluate the anti-TNFα activity of antibody formulation as in vivo experimental model. SD
sample consisting of 36 mg trehalose, 12 mg cysteine, and 0.05% of Tween 20 was selected
with minimum aggregation/fragmentation rate constants of 0.07 and 0.05 (1/month) based on
1 and 2 months of storage at 40°C and relative humidity of 75%. Fine particle fraction (FPF)
value of this formulation was 67.75% with desired particle size and surface morphology for
respiratory delivery. EC50 was 8.176 and 6.733 ng/ml for SD Infliximab and Remicade®,
respectively. SD antibody reduced TNFα (26.56 pg/ml) secretion in mouse lung tissue, more
than 2 orders of magnitudes comparing positive control group (TNFα, 68.34 pg/ml). The
success of antibody inhalation mainly depended on the spray drying condition, formulation
components, and stability of antibody within aerosolization. Inhaled Infliximab could be a
potential drug for local inhibition of lung inflammation.
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INTRODUCTION
Asthma is the most prevalent chronic disease in the
world and significant populations of patients are resistant to
the systemic corticosteroids and high doses of bronchodilators
(1). New approaches in the treatment of asthma are based on
suppression of inflammatory pathways and prevention of
structural changes in the airways (2,3).
Lung levels of pre-inflammatory cytokines like tumor
necrosis factor α (TNFα) are increased in asthma. TNFα as a
non-glycosylated protein is involved in pathogenesis of
asthma, rheumatoid arthritis, multiple sclerosis, and other
types of inflammatory disorders (4,5). The mRNA of TNFα is
over-expressed in the airways of asthmatic patients. There-
fore, inhibition of TNFα could be a reasonable approach in
the treatment of asthma (6).
Infliximab, as a chimeric monoclonal antibody (mAb)
against TNFα, was approved by FDA for the treatment of
rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis
(7). In patients with simultaneous asthma and rheumatoid
arthritis, administration of Infliximab was encouraged in
alleviation of respiratory symptoms (8); moreover, the
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reduction of inflammatory markers as well as variations in
peak expiratory flow rate and exacerbation were observed
in asthmatic patients through application of Infliximab (9).
Inhalation of therapeutic proteins, such as antibodies, can
provide an encouraging opportunity for their needle-free
delivery, high drug bioavailability, low required dose, and
patient compliance especially in the case of chronic diseases
(10).
Spray drying is regarded as a method of choice for
embedding proteins, as labile molecules, in stabilizing
additives like sugars, amino acids, and other types of
carriers (11). Although incorporation of suitable excipients
could enhance the efficacy of spray-dried (SD) protein
powders, preparation of stable powder of mAbs for
inhalation therapy still remains a bit challenging. Besides,
limitations such as low efficiency in local delivery of exact
dose and low repeatability of inhalation devices should be
considered (12). Our previous studies on optimization of SD
intravenous immunoglobulin (IVIG) and Trastuzmab fo-
cused on molecular stability, as well as particle behavior
(13,14) of processed powders. Furthermore, screening the
effect of different amino acids was done which suggested
cysteine as the amino acid of choice in SD IgG formulations
(15). Also experimental design was utilized to determine the
best quantitative combination of IgG formulation in the
presence of trehalose, cysteine, and Tween 20 (16).
The present study was designed to further evaluate the
feasibility of respiratory delivery of Infliximab as a suitable
alternative to its systemic administration. In order to assess
the hypothesis, SD preparations were characterized consid-
ering biological activity in vitro and in a mouse model of
inflammation.
MATERIALS AND METHODS
All sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) reagents, disodium hydrogen phos-
phate, sodium sulfate, trehalose dihydrate, actinomycin D,
methyl tetrazolium (MTT) solution, ovalbumin, ketamin,
xylazine, acetonitrile, alum, trypsin, potassium bromide
(KBr) as well as dialysis tubing membrane were supplied by
Sigma, UK. Polysorbate 20 (Tween 20) was obtained from
Merck, Germany. Infliximab was provided by Jenssen Bio-
tech, USA. Roswell Park Memorial Institute (RPMI)-FBS
was supported by Gibco, USA. The cell line L-929, adherent
fibroblast-cell line derived from subcutaneous connective
tissue of mouse, was offered by American Type Culture
Collection (ATCC), USA. Gelatin capsules of size 3 were
kindly gifted by Cipla, India. Mouse-TNF α enzyme-link
immunosorbent assay (ELISA) kit from Abnova was utilized
for in vivo assay, assessment of TNF α level in a mouse model
of inflammation. Data were measured and reported as means
± SD. One-way ANOVA, SPSS 16, was done to assess the
significant differences between prepared formulations. The
results were considered with a p value less than 0.05 as
significant. The graphs were drawn by Graph Pad® Prism 5.
Preparation of Formulations and Spray Drying
Freeze-dried (FD) powder of Infliximab (Janssen Bio-
tech, USA) was dissolved in sterile WFI and transferred into
a dialysis tubing (cutoff, 8 kDa), shaking overnight at 4°C. A
final pure antibody mount was 30 mg for each formulation.
Based on the compositions presented in Table I, the F1-F10
formulations were prepared, sterile filtered by 0.22 μm filters,
and kept at 4°C prior to spray drying. Lab-scale spray dryer
(Buchi 191, Switzerland) was applied to prepare dry powders
of antibody. The standard operating conditions were as
follows: drying air inlet temperature of 100°C, aspiration
setting of 100%, and liquid feed rate of 10% (1.8 ml/min).
This operational condition resulted in an average outlet
temperature of 56°C. The recovered powders in the collection
vessel were collected and stored at 4°C in sealed glass vials
for further examinations.
Size Exclusion Chromatography (SEC-HPLC)
The percentage of antibody monomer and the presence
of high molecular weight (aggregates) as well as low
molecular weight species (fragments) were determined by
SEC-HPLC analysis. SEC-HPLC column (TSK Gel
G3000swxl, Silica gel column, Tosoh, Germany) was applied
to inject 20 μl of 0.45-μm filtered samples at final concentra-
tion 2.5 mg/ml of antibody. The HPLC system (Jascow,
Japan) was equipped with a pump and a UV detector at
214 nm. Mobile phase consisted of 0.1 M disodium hydrogen
phosphate and 0.1 M sodium sulfate with pH adjusted at 6.8.
The injections were performed in isocratic mode at running
time of 35 min for each sample in triplicate. The Unicorn
software (GE, Sweden) was used to calculate the area under
the curve (AUC) of monomer peak to that of induced
antibody aggregates and/or fragments after spray drying as
well as upon 1 and 2 months of storage at 40°C and relative
humidity of 75%. The percent of aggregates, fragments, and
monomer were quantified through integrating each peak area
as have been shown below:
Aggregates (%) =AUC aggregates (%) / AUC
total peaks (%)
Fragments (%) =AUC fragments (%) / AUC total
peaks (%)
Table I. Composition of SD Infliximab Formulations. Excluding F1,








M a s s
ratio
F1 30 – –
F2 30 1:1 1:5
F3 30 1.2:1 1:5
F4 30 1.4:1 1:5
F5 30 1:1 1:3.33
F6 30 1.2:1 1:3.33
F7 30 1.4:1 1:3.33
F8 30 1:1 1:2.5
F9 30 1.2:1 1:2.5
F10 30 1.4:1 1:2. 5
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Natural logarithm of aggregates/fragments (%) was
plotted versus storage time (1 and 2 months). The rate of
fragmentation/aggregation was calculated considering first-
order kinetic trough linear regression of the prepared plot.
FTIR Spectroscopy
Infrared spectra were measured applying a spectrometer
(Nicolet Magna, USA). Two milligrams of SD powders was
mixed with 200 mg KBr and pressed through 6–7 T of
pressure (Carver press, USA). The analysis of amide I region
(1600–1700 cm−1) was performed to determine the secondary
structure of Infliximab as a beta-dominant protein. Jasco
Spectra Manager Software facilitated fitting through a mixed
Gaussian/Lorentzian function. The position of peaks for IgG
was described as follows: The peaks located at 1640 cm−1 as
well as 1690–1695 cm−1 are attributed to β-sheet structures,
peaks from 1660 to 1650 cm−1 are indicative of α helix, and
turn structures are positioned from 1690 to 1665 cm−1 (17).
Electrophoretic Analysis (SDS-PAGE)
SDS-PAGE is an established technique to compare the
integrity of the protein solution with the standard sample. In
SDS-PAGE, proteins are resolved on polyacrylamide gel
based on their overall molecular weight and banding pattern
formed can be compared between reference and test solution
to confirm the integrity of protein following spray drying
procedure. Non-reducing SDS-PAGE (Bio-Rad, USA) was
carried out preparing 12% gel. About 20 μl of prepared
samples (containing 100 μg/ml of antibody) was loaded at
voltage 220 V for 3 h. The resolving gel was stained with
Coomassie blue for visualization of antibody related bands in
SD Infliximab formulations and comparison with those of
Remicade.
Particle Size Analysis Via Laser Light Scattering
Laser light scattering (Malvern Mastersizer, UK) was
employed to calculate particle sizes. Five milligrams of SD
samples was suspended in 10 ml of acetonitrile and sonicated
trough water-bath sonicator (Starsonic, Italy) for 5 min to be
fully homogenized. Obscuration from 0.15 to 0.2 was applied
to measure particle sizes in triplicate for each sample.
Inhalation Performance of SD Infliximab Formulation
Aerosolization efficacy of SD powders was characterized
through TSI (Apparatus A, 2000, Copley, UK). Approxi-
mately, 15 mg of selected powders (F1 and F10) was filled in
HPMC capsule of size 3 and was placed in a Cyclohaler®.
The capsules (three capsules for each formulation) were
emptied from the Inhalator at 60 l/min for 5 s using vacuum
pump (P 504, Cole Parmer, UK). The upper and lower stages
of TSI were rinsed with 7 and 30 ml of purified water,
respectively, and the amount of Infliximab was quantified by
spectroscopy method, at 280 nm. Temperature and relative
humidity were controlled at 25°C (± 1°C) and 40–45%
respectively for all experiments. The deposition profile of
selected formulations was characterized through calculation
of fine particle fraction (FPF) as well as emitted dose (ED).
The ED is regarded as the total amount of collected powder
at all stages. Fine particle dose (FPD) is the total amount of
powders with particle size < 6.4 μm which deposited in the
lower stage of TSI. FPF is obtained through division of FPD
to the ED (18).
Scanning Electron Microscopy
The surface morphology of selected formulations was
investigated utilizing scanning electron microscopy (SEM)
system (XL30, The Netherlands). Powder samples were
mounted on top of an aluminum stub and sputter coated
(BAL-TEC, Switzerland) with gold at 100 Pa (75 mTorr), for
90 s at room temperature. The images were scanned at
accelerating voltage of 20 kVand magnifications of ×1000 and
×15,000.
In Vitro Biological Activity of SD Infliximab Versus
Remicade®
SD Infliximab bioactivity was quantified by L929 cells.
TNFα causes lysis of L929 cells after sensitization with
actinomycin D. Antibodies bound to human TNFα neutral-
ized the effect, resulting in the rescue of L929 cells from cell
lysis. Briefly, cells were seeded on sterile 96-well plates (2.5 ×
104 cells/well) in 50 μl of DMEM F12 supplemented with 10%
FBS. One hundred microliters of different concentrations of
SD Infliximab or Remicade (0.1–100 ng/ml) was added to the
cells. Afterward, 50 μl of TNFα solution (50 pg/ml) was
added to each well. In the negative control sample, no TNFα
was present. Cells were incubated for 72 h at 37°C in the CO2
incubator (Shel lab, USA). The optical density of the well (at
620 nm) is directly proportional to the concentration of live
cells in each well with the aid of MTT assay. The cell viability
was plotted against the monoclonal antibody concentration to
assess comparability of biological activity between F9 and
Remicade.
Animals, Induction of Airway Sensitization, and Challenge
Female balb/c mice (6–8 weeks old) were donated by
Pasteur Institute of Iran. All the animal experiments were
conducted under a protocol approved by committee of
medical ethics at Tehran University of Medical Sciences.
The protocol was in accordance with National Institutes of
Health guide for animals (NIH Publications No. 8023, revised
1978). Mice were categorized into three groups and each
group consisted of five mice (group 1, negative control; group
2, positive control; and group 3, test). The experimental
protocol was described in Table II. All groups were generally
sensitized through intraperitoneal (i.p.) injection of 50 μg
ovalbumin on days 0, 7, and 14. Groups 2 and 3 received
500 μg, intratracheal (i.t.) ovalbumin on days 21–27. Twenty
micrograms/day of SD Infliximab powder was administered
via trachea and with the aid of insufflator, 3 h before
challenge test in group 3, on days 21–28. Prior to i.t.
injections, mice were anesthetized by 100 μl, i.p. injection of
ketamin/xylazine (10:1). For i.t. injection, mice were fixed on
special boards, the tongue of the mice was brought out by
sterile forceps, the insufflator was put precisely in the trachea
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of the mice, and finally the powder of the drug was placed in
the trachea with the aid of insufflators.
Bronchoalveolar Lavage and Sample Preparation for ELISA
Test
Mice were sacrificed on day 29, after being anesthetized.
The lungs were meticulously excised and washed with 1 ml
PBS buffer three times. The lavage fluid was homogenized
with ultrasonic hemogenizer (IKA T25, Germany) for 15 s
and then centrifuged at 800 rpm for 10 min at 4°C. The
supernatants were stored at − 20°C for further experiments.
Enzyme-Link Immunosorbent Assay
Mouse-TNFα ELISA kit (KA0257, Abnova, Taiwan)
was applied to quantify level of TNFα in the lung tissue of
three mice groups. Present TNFα in each sample was
captured by the antibody immobilized to the wells and by
the biotinylated TNFα-specific detection antibody. After
washing away unbound biotinylated antibody, HRP-
conjugated streptavidin was pipetted to the wells. The wells
were again washed. Following the second wash step, TMB
substrate solution was added to the wells, resulting in color
development proportional to the amount of bound TNFα.
The Stop Solution changed the color from blue to yellow, and
the intensity of the color was measured at 450 nm
(BioSpectrometer, Eppendorf). The standard curve was
generated by plotting the average O.D. (450 nm) obtained
for each of the standard concentrations on the vertical (Y)
axis versus the corresponding TNFα concentration (pg/ml) on
the horizontal (X) axis. TNFα was diluted in the range from
62.5 to 2000 pg/ml. The content of secreted TNFα in three
groups was quantified by comparison with a standard curve.
RESULTS AND DISCUSSION
TNFα as a pro-inflammatory cytokine has been proved to
be in charge of airway pathology in asthma (19). Anti-TNFα
therapy in preliminary studies confirmed better lung function,
lower airway hyperresponsiveness (AHR), and less frequency
of exacerbation in patients with refractory asthma (20). In a
clinical study composed of 38 patients with moderate asthma,
intravenous infusion of Infliximab caused reduction in the
number of exacerbated patients. Likewise, significant decrease
in level of TNFα was inspected in sputum supernatants without
any serious adverse reactions (21). In prospect of developing an
inhalable form of Infliximab, for local inhibition of TNFα in
inflammatory asthma, spray drying was investigated to process
stable dry powder employing combination of stabilizers. In the
subsequent parts, the characterization of samples has been
discussed with respect to stability aspects, particle features,
in vitro biological activity as well as in vivo suppression of TNFα
in a mouse model.
Physicochemical Stability of SD Infliximab
SEC-HPLC was utilized to quantify the amount of
induced aggregates/fragments of antibody in the formulations
after spray drying process and at 1 and 2 months of storage at
40°C (Table III). The results were then engaged to calculate
the rate constants of aggregation/fragmentation regarding the
first-order kinetic of degradation (chromatograms of F1, F9,
and Remicade were provided as Fig. 1AA, B, C supplement).
Pure antibody was statistically less stabilized against aggre-
gation and fragmentation comparing formulated samples
(one-way ANOVA, SPSS 16, Table file 1 supplement), with
p value < 0.05. F1 showed the highest rate of fragmentation
and aggregation with corresponding values of 0.14 ± 0.001 and
0.15 ± 0.004 (1/month), respectively. The least rate constant of
fragmentation and aggregation was observed in F7 (0.06 ±
0.002 and 0.07 ± 0.002, 1/month) and F9 (0.05 ± 0.001 and 0.07
± 0.002, 1/month). Considering the most value of statistical
differences between F9, with other samples, it was selected as
the physically stable sample for further analysis (one-way
ANOVA, SPSS 16, Table file 2 supplement). The superiority
of F9 was statistically proved in terms of aggregation
comparing all powders excluding F7 and F10 after process
and 1 month storage, p value < 0.05; after 2 months of storage
was similar to F4 and F7. With regard to fragmentation, F9
was better than F1 after process and 1 month storage, p value
< 0.05; after 2 months of storage F9 was statistically preserved
against aggregation better than F1, F2, and F5, p value < 0.05.
The overall conclusion was derived that F9 was the most
stable powder with respect to molecular stability profile.
To confirm the preserved integrity of antibody, SDS-
PAGE analysis was performed under non-reducing condition
(Fig. 1). The single band at 150 kDa appeared in all
formulations without any remarkable bands at the upper or
lower areas. Such observation implied the fact that under the
Table II. Experimental Protocol for Sensitization, Challenge, and Antibody Administration
Group Day 0 Day 7 Day 14 Days 21–28 Day 29






Challenge: no BA lavage
Treatment: no



















Treatment: 20 μg/day SD Infliximab
(i.t.) 3 h before challenge test
OVA ovalbumin, BA bronchoalveolar, SD spray-dried
128 Page 4 of 9 AAPS PharmSciTech (2019) 20: 128
selected conditions, processing of Infliximab formulations
protected protein against fragmentation within spray drying.
Thermodynamic Properties of SD Antibody
FTIR spectroscopy was conducted to evaluate the
structural changes in secondary conformation of SD
Infliximab. A mixed Gaussian-Lorentzian curve-fitting analy-
sis was employed to record the alterations in amide I region.
In the amide I region, peaks were present at 1690, 1670, 1640,
and 1620 cm−1 (22). Based on the second-derivative spectrum
achieved from F1 (Fig. 2), pure Infliximab has major β-sheet
attributed bands at 1640, 1620, and 1690 cm−1 and a turn-
specific band at 1670 cm−1 which is typical for a monoclonal
antibody (23). The FTIR analysis of F1–F10 demonstrated
that the solid formulations of Infliximab retained properly in
the native-like structure with predominantly β-sheet content
ranging from 68.71 ± 1.34 to 70.95 ± 1.89% (Table III). Con-
clusively, there was no significant difference in the conforma-
tion of F1 with that of F2–F10 regarding β-sheet percent.
Similar to the findings of our previous publication, the
mass ratio of amino acid/antibody, 0.4:1, and sugar/antibody,
1.2:1, produced the best stabilized composition through the
properly sufficient interaction with antibody molecules within
process and during storage at high temperatures (16).
Physical Properties and Aerodynamic Behavior of
Microparticles
After each spray drying run, collected samples were
weighed for calculation of process yield (Fig. 3a). The
achieved data from the process yield was in good agreement
with the hydrophobicity of powders. F1 had the lowest
powder recovery amount of 20.33 ± 2.31%. The highest value
of yield was attained in F8 (38.7 ± 1.24%) which was
composed of 12 mg cysteine and 30 mg trehalose, besides
0.05% of Tween 20. As general evidence and in accordance
with previously developed experimental design (16), higher
amounts of cysteine (as a hydrophobic component) and lower
amounts of trehalose (as a hydrophilic excipient) were
accounted for efficient powder recovery. Formation of
hydrophobic particles with lower adhesiveness to the cyclone
chamber aided powder fluidization and therefore, increased
the amounts of collected powder.
The deposition of inhaled particles at various levels of
respiratory system is dependent on the particulate character-
istics namely particle size and morphology which affect the
aerosolization properties of SD powders (24). To obtain
enhanced drug deposition and residence time, particles must
have aerodynamic diameters less than 6.4 μm (25). Laser light
scattering data revealed that the geometric sizes of all
particles (F2–F10) were in the acceptable range, from 4.03 ±
0.22 to 5.22 ± 0.54 μm, Fig. 3b).
Two basic conclusions could be derived. First, increasing the
amount of cysteine to 12mg decreased the particle sizes. Cysteine
as a hydrophobic amino acid reduced the inter-particle forces and
Table III. Molecular and Structural Stability of SD Infliximab Formulations
















F1 0.95 ± 0.02* 1.18 ± 0.01* 1.85 ± 0.01* 1.69 ± 0.02* 2.35 ± 0.01* 3.37 ± 0.01* 0.14 ± 0.001* 0.15 ± 0.004* 68.71 ±
1.34*
F2 0.31 ± 0.05 0.38 ± 0.01 0.46 ± 0.08 0.87 ± 0.03 1.07 ± 0.01 1.36 ± 0.03 0.09 ± 0.002 0.10 ± 0.002 69.25 ± 1.45
F3 0.21 ± 0.01 0.25 ± 0.05 0.30 ± 0.03 0.63 ± 0.03 0.75 ± 0.01 0.98 ± 0.03 0.08 ± 0.002 0.10 ± 0.002 69.44 ± 1.23
F4 0.20 ± 0.03 0.23 ± 0.04 0.27 ± 0.09 0.47 ± 0.05 0.55 ± 0.03 0.70 ± 0.02 0.07 ± 0.001 0.09 ± 0.003 70.23 ± 2.31
F5 0.29 ± 0.05 0.34 ± 0.02 0.40 ± 0.04 0.71 ± 0.02 0.85 ± 0.02 1.14 ± 0.02 0.07 ± 0.002 0.10 ± 0.001 69.37 ± 2.14
F6 0.19 ± 0.01 0.23 ± 0.02 0.26 ± 0.02 0.59 ± 0.02 0.70 ± 0.02 0.83 ± 0.02 0.07 ± 0.003 0.07 ± 0.002 70.52 ± 1.34
F7 0.16 ± 0.03 0.18 ± 0.05 0.21 ± 0.06 0.17 ± 0.01 0.20 ± 0.02 0.24 ± 0.03 0.06 ± 0.002 0.07 ± 0.002 70.54 ± 2.12
F8 0.24 ± 0.02 0.28 ± 0.05 0.33 ± 0.02 0.55 ± 0.02 0.64 ± 0.01 0.86 ± 0.02 0.07 ± 0.001 0.10 ± 0.001 70.12 ± 1.24
F9 0.12 ± 0.01* 0.13 ± 0.05* 0.15 ± 0.05* 0.08 ± 0.01* 0.09 ± 0.01* 0.11 ± 0.02* 0.05 ± 0.001* 0.07 ± 0.002* 70.61 ± 1.67
F10 0.19 ± 0.01 0.22 ± 0.02 0.26 ± 0.07 0.10 ± 0.01 0.12 ± 0.01 0.15 ± 0.02 0.07 ± 0.001 0.09 ± 0.002 70.95 ± 1.89
p value less than 0.05 is considered as statistically significant. *: F1 is statistically different to other samples with p value < 0.05. *: F9 for
aggregation is significantly different to other formulations excluding F7 with p value < 0.05. For fragmentation, F9 was different to F1, F2, and F5
with p value < 0.05. For rate constants of degradation, F9 meaningfully differs from F1 with p value < 0.05
1,2 45 degree centigrade
Fig. 1. Non-reducing SDS-PAGE of Infliximab formulations. From
right to left: lane 1, Remicade; lane 2, F1; lane 3, F2; lane 2, F3; lane 5, F4;
lane 6, F5; lane 7, F6; lane 8, F7; lane 9, F8; lane 10, F9; lane 11, F10; and
lane 12, standardmarker (11, 17, 25, 35, 48, 63, 75, 100, 135, and 180 kDa)
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prevented the formation of cohesive and larger particles.
Secondly, in each amount of cysteine (6, 9, and 12 mg), increasing
the trehalose amounts from 30 to 42 mg led to the formation of
larger particles as a result of the hydrophilic nature of trehalose
and creation of sticky particles. Creation of agglomerated particle
was previously reported in SD protein containing trehalose (26);
however, incorporation of a surfactant (e.g., Tween 20) in addition
to hydrophobic amino acid (cysteine) prevented the powders
from agglomeration and particle sizes in all preparations were less
than 6 μm. Comparing F1 with aerodynamic diameter of 7.81 ±
0.71 μm, F2–F10 showed lower sizes, acceptable for further
respiratory delivery.
TSI was employed as an in vitro simulation device for
evaluation of aerosol performance of SD powders. The ED
and FPF of formulations have been compared in Fig. 3a. All
samples exhibited better aerosol performance in comparison
to F1. The amounts of ED varied from 70.46 ± 1.43 to 93.21 ±
1.24%. Apart from F1–F4, all preparations demonstrated
FPFs higher than 60%. As a general finding, formulations
containing the highest levels of cysteine and the lowest
amounts of trehalose showed maximum FPFs which is surely
due to hydrophobic nature of cysteine. The best deposition
was observed for F8 and F9 with respective FPF values of
68.65 ± 1.34 and 67.75 ± 1.29%.
Both the device and powder formulation must provide
high FPF of the powder to be delivered to the respiratory
system. The bulk combination of additives should successfully
facilitate the actuation of powder during administration.
Similar findings were reported through incorporation of
trileucine in SD powders of human growth hormone and
salmon calcitonin (27). Low aqueous solubility of hydropho-
bic amino acids (e.g., trileucine) facilitated the formation of
corrugated particles with low density which promoted supe-
rior aerosolization of powder. In agreement with the present
data, highly wrinkled, raisin-like particles conferred improved
particle size and FPF, while spherical ones with smooth
surface were not desirable respecting aerosolization efficacy
(28).
The SEM photograph of F9, as selected powder, is
presented comparing F1 (Fig. 4a, b). Pure SD Infliximab
formed coherent and smooth surface particles (F1), while in
the presence of cysteine raisin-like particles were produced
(F9). High surface area created by cysteine was reasonably
accounted for the corresponding high deposition performance
(FPF value of 67.75 ± 1.29%).
In Vitro Biological Activity of Antibody
Since the alteration in mAb higher order structure leads
to loss of bioactivity, assessment of biological activity is
regarded as the key parameter in formulation development.
The comparable bioassay could imply preservation of sec-
ondary, tertiary, and quaternary structures of related protein
as well (29). Infliximab mechanism of action is attributed to
TNFα binding, cell apotosis, induction of ADCC, and
activation of complement system (30); however, its biological
activity mainly depends on the ability to target TNFα. An
overall reduction in inflammation occurs as a result of TNFα
neutralization.
Fig. 2. FTIR spectrum of SD pure Infliximab powder (F1). The fitted-trace, the original spectrum
of SD pure antibody, and the calculated (curve-fitted) bands have been colorfully distinguished
Fig. 3. Particle properties of SD Infliximab powders. a Particle size (μm). b Yield, FPF and ED (%)
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In order to compare the processed formulation with
reference standard, the measurement of cell viability was
performed in the presence of dilution series of F9 and
Remicade®. Various antibody concentrations were added to
the culture of L-929 cell line and following incubation, the cell
viability was calculated applying calorimetric MTT assay. The
absorbance of plate containing Remicade® and F9 was
measured at 620 nm. Both Remicade® and F9 should
neutralize the cytotoxic effect of TNFα on L-929 cell line.
Increasing the ratio of antibody enhanced cell viability in
both formulations. The cell viability was 99.8 and 92%, at
1000 ng/ml for Remicade and F9. Based on the data presented
in Fig. 5 (non-linear regression, Graph pad prism software,
version 6.01), EC50 was 8.176 and 6.733 ng/ml for F9 and
Remicade®, respectively. To further assess the efficacy of
formulation components on biological activity of Infliximab
powder, EC50 of F1 additionally calculated which was
11.20 ng/ml.
The comparison of formulations indicated the acceptable
preservation of structure and efficacy of dry powder formu-
lation of Infliximab. F9 was maintained at high TNFα binding
affinity in comparison to Remicade®. This study confirmed
that spray drying stresses and especially high temperature
could be desirably controlled in the presence of efficient
excipients so that the structural stability and biological
activity of antibody could be maintained more than 82% of
Remicade®. Similar to the current results, spray drying was
reported as a successful method for processing Infliximab
powder with retained stability and successful TNFα binding
(31). Also in a same procedure of spray drying, Trastuzumab
affinity to HER2 antigen was compared with that of
Herceptin employing ELISA method. Preserved affinity of
antibody to antigen was 86.5% in a SD sample comparing
100% affinity in Herceptin (32). Lower biological activity of
F9 versus SD Trastuzumab might be attributed to the
sensitivity and instability of chimeric monoclonal antibody
when compared to humanized ones.
Anti-Inflammatory Effect of Processed Antibody in an
Allergen-Induced Mouse Model
To further confirm the influence of F9, in vivo evaluation
was designed in a mouse model of inflammation. The
characteristics of three groups as well as applied regimen
are presented in Table II. TNFα titer in the lung tissue of
killed mice was quantified by ELISA method. The standard
curve was drawn based on average absorbance at 450 nm
versus TNFα concentration (Fig. 2 supplement). The absor-
bance of the test, positive control, and negative control
groups was determined according to the standard curve at
450 nm (Fig. 6).
As it is evident, comparing positive control group (with
TNFα secretion concentration of 68.34 pg/ml), in the test
group, lung TNFα secretion was significantly reduced
(26.56 pg/ml) which proved the efficacy of F9 in inhibition of
cytokine secretion and subsequent induction of inflammation
(one-way ANOVA, SPSS 16, Table file 3 supplement).
Fig. 4. SEM images of a SD pure Infliximab powder (F1), and b F9
(composed of 30 mg Infliximab, 36 mg trehalose, 12 mg cysteine, and
0.05% Tween 20)
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The lung serves as a local target for treatment of lung
diseases including tuberculosis, lung cancer, cystic fibrosis,
and asthma. Rapid onset of action along with favorable
bioavailability caused drug molecules to be favorably admin-
istered via inhalation for lung target therapies (33). Lung
delivery of monoclonal antibodies has presented satisfactory
results in some previous investigations (34). Previously,
administration of single dose (1 mg, i.p.) of Infliximab was
reported to reduce the mouse allergic rhinitis following
almost similar challenge protocol (35).
Furthermore, aerosolized inhaled mAbs against T cell
receptor could successfully manipulate T cell activity in the
airways and ameliorate AHR and inflammation in mice (36).
Anti-CD49d antibody was administered both through i.p.
(800 μg) and i.n. (300 μg) to compare the efficacy of systemic
and local drug delivery. It was concluded that i.n. delivery
blocked CD49d receptors in the airways, suppressed inflam-
mation, and reduced IL-4 and IL-5 secretion. On the opposite
site, eosinophilia was observed through systemic administra-
tion of drug (37).
Regarding the prospects of mAb pulmonary delivery for
the treatment of respiratory dysfunction, inhaled
Omalizumab (anti-IgE mAb) failed to subside the reaction
of asthmatic patients to induced allergy (38). Lack of
functionality of the drug was likely attributed to low systemic
drug concentration in the blood stream for inhibition of
secreted-IgE (39).
Considering the pulmonary delivery of Infliximab as a
feasible method for local treatment of asthma, some chal-
lenges remain yet to be circumvented such as anti-drug
antibodies (ADA) as a measure of immunogenicity. The
formation of immune complexes between ADA and mono-
clonal antibody can cause adverse effects including hypersen-
sitivity reactions and neutralization of drug effect (40);
therefore, the formation of human anti-chimeric antibodies
may promote immune responses in patients with asthma, as a
chronic inflammatory disease, and should be further evalu-
ated in human clinical examinations.
CONCLUSION
Interest in local delivery of mAbs to the lung is
growing as a potential means of boosting the efficacy and
limiting the systemic adverse effects of drug. This study
confirmed the feasibility for the pulmonary delivery of
Infliximab. Remarkably, the spray drying process with the
applied excipients preserved the antibody from gross
aggregation and fragmentation. Additionally, antibody
bioactivity was well-retained and functional binding with
TNFα occurred. Although F9 could prevent high TNFα
levels following challenge test, elimination mechanisms of
antibodies from the lung namely macrophages and
mucociliary routes are still unavoidable which should be
resolved in further experiments.
Publisher’s Note Springer Nature remains neutral with regard
to jurisdictional claims in published maps and institutional
affiliations.
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